Endeavor BioMedicines has concluded patient enrolment in a Phase IIa clinical trial of ENV-101 (taladegib) to treat idiopathic pulmonary fibrosis (IPF).

The multi-centre, placebo-controlled, randomised study is being carried out in Mexico, Canada, and the Asia-Pacific region.

It intends to assess the efficacy and safety of the Hedgehog (Hh) signalling pathway inhibitor ENV-101 in patients with mild-to-moderate IPF.

A total of 41 participants aged 40 years and above will receive daily ENV-101 as a monotherapy or placebo for 12 consecutive weeks.

They will also be observed for an additional six weeks following the treatment with ENV-101.

A change from baseline in frequency, severity of adverse events, and a change in key vital sign measurements are the primary endpoints of the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Secondary endpoints include a change in forced vital capacity and other measures of lung function.

Endeavor BioMedicines co-founder, CEO and chairman John Hood said: “Completing enrolment in the ENV-101 IPF study brings us one step closer to delivering an urgently needed therapy with the potential to treat the underpinnings of the disease and halt the progression of fibrosis.

“This enrolment milestone is an important achievement, and we look forward to reporting topline results in Q1 of 2024.”

The company’s lead programme, ENV-101 is a small-molecule agent that induces myofibroblast apoptosis and eliminates the key cellular driver of IPF.

Last May, the company dosed the first patient in its open-label Phase II study of ENV-101 to treat advanced solid tumours harbouring Patched-1 (PTCH1) loss of function mutations.